**

Overview

Proteomics emerged as the logical next step after the completion of the Human Genome Project (2003), translating the static list of genes into dynamic, functional molecules. While a genome provides the blueprint, the proteome reflects the real‑time state of a biological system, capturing post‑translational modifications, isoforms, and protein‑protein interactions that dictate phenotype. Modern proteomics combines high‑throughput mass spectrometry (MS), advanced separation techniques (e.g., two‑dimensional gel electrophoresis, liquid chromatography), and powerful bioinformatics pipelines to identify and quantify thousands of proteins in a single experiment.

A typical proteomic workflow begins with sample preparation—cell lysis, protein extraction, and enzymatic digestion (commonly with trypsin). The resulting peptide mixture is separated by nano‑LC (liquid chromatography) and introduced into a mass spectrometer, where ions are measured with accuracies often better than 5 ppm. Tandem MS (MS/MS) fragments selected ions, generating spectra that are matched against databases derived from genome sequences. Quantitative strategies such as label‑free intensity, SILAC (stable isotope labeling by amino acids in cell culture), or TMT (tandem mass tags) enable comparative studies across conditions, disease states, or developmental stages.

Beyond cataloguing proteins, proteomics interrogates protein structure (via cross‑linking MS, hydrogen‑deuterium exchange) and interactome networks (through affinity purification MS). These layers provide insight into signaling pathways, metabolic fluxes, and cellular responses to external stimuli, positioning proteomics as a cornerstone of functional genomics and systems biology.

History/Background

The term “proteome” was coined in 1995 by Marc Wilkins, envisioning a comprehensive protein inventory analogous to the genome. Early proteomic efforts relied on 2‑D gel electrophoresis, which could resolve ~1,000 protein spots per gel but suffered from limited dynamic range and poor reproducibility. The breakthrough came in 1999 with the introduction of MALDI‑TOF (matrix‑assisted laser desorption/ionization time‑of‑flight) mass spectrometry, dramatically increasing throughput and sensitivity.

In 2002, the Human Proteome Project (HPP) was launched under the Human Proteome Organization (HUPO), aiming to map all human proteins by 2020—a goal that spurred the development of standardized protocols, reference reagents, and community databases such as ProteomeXchange. The advent of Orbitrap and Q‑TOF instruments in the mid‑2000s delivered sub‑ppm mass accuracy and high resolution (>100,000 FWHM), enabling routine identification of low‑abundance proteins. By 2010, label‑free quantitation and isobaric tagging had become mainstream, and the first draft of the human proteome was announced in 2014, covering ~90 % of predicted proteins.

The last decade has seen single‑cell proteomics emerge, leveraging nanodroplet sample preparation and ultra‑sensitive MS to detect >1,000 proteins from individual cells (2022). Parallel advances in deep learning for peptide‑spectra matching and ion mobility separation have further expanded depth and speed, positioning proteomics as a mature, high‑resolution “omics” discipline.

Key Information

- Proteome size: An average human cell expresses ~10,000–12,000 distinct proteins, with many existing as multiple post‑translationally modified (PTM) forms. - Analytical platforms: Orbitrap Fusion Lumos (resolution 500,000 at m/z 200), timsTOF Pro (ion mobility, >1 M MS/MS per day). - Quantitative methods: SILAC (incorporates ^13C/^15N isotopes), TMT‑16plex (allows simultaneous analysis of 16 samples). - Databases: UniProtKB/Swiss‑Prot, PRIDE Archive ( >30 million spectra as of 2023), PeptideAtlas. - Major achievements: Identification of disease biomarkers for cancers, neurodegenerative disorders, and infectious diseases; mapping of the human interactome (>200,000 binary interactions); elucidation of drug‑target engagement via thermal proteome profiling. - Technical metrics: Typical peptide‑level false discovery rate (FDR) <1 %; protein‑level FDR <0.5 %; dynamic range spanning >5 orders of magnitude in modern workflows.

Significance

Proteomics bridges the gap between genotype and phenotype, providing a functional read‑out that genomics alone cannot deliver. In medicine, proteomic signatures guide precision oncology, informing treatment selection based on tumor‑specific protein expression and phosphorylation patterns. In biotechnology, proteomics monitors biopharmaceutical production, ensuring product quality by detecting host‑cell protein contaminants at parts‑per‑million levels. Environmental sciences employ proteomics to assess organismal responses to pollutants, while agriculture leverages it to improve crop resilience through stress‑responsive protein networks.

The field’s interdisciplinary nature—melding chemistry, biology, engineering, and computer science—has catalyzed innovations such as microfluidic sample preparation, cloud‑based data analysis, and AI‑driven peptide identification. As proteomics continues to scale down to single cells and up to whole‑organism atlases, it promises to unlock deeper mechanistic insights, transform diagnostics, and accelerate drug discovery, cementing its role as an indispensable pillar of modern life sciences.

INFOBOX:
- Name: Proteomics
- Type: Omics discipline (large‑scale protein science)
- Date: Concept introduced 1995; major methodological milestones 1999–2022
- Location: Global research community (academic, industry, clinical labs)
- Known For: Systematic identification, quantification, and functional analysis of the proteome

TAGS: proteomics, mass spectrometry, functional genomics, protein–protein interactions, biomarker discovery, single‑cell analysis, post‑translational modifications, systems biology